Lannett To Launch Into Congested ADHD Market

Lines Up Latest Rival To Adderall XR

Lannett expects soon to launch a generic rival to Adderall XR following FDA approval for its partner SunGen. But the US generics specialist will face considerable competition.

Adderall
Lannett is poised to be the latest company offering a US generic rival to Adderall XR • Source: Shutterstock

Lannett expects “in the coming months” to start marketing in the US a generic version of Shire’s Adderall XR (dextroamphetamine saccharate/amphetamine aspartate/dextroamphetamine sulfate/amphetamine sulfate) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets. But the US generics specialist will enter an already highly competitive market for the attention deficit hyperactivity disorder and narcolepsy drug.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

More from Generics Bulletin